COVID-19：NEC，SARS-CoV-2基因分析结果发布：NEC肿瘤免疫（NOI）
COVID-19：NEC
NEC：
我们发布了使用AI对新冠状病毒（SARS-CoV-2）进行基因分析的结果。
这将是支持疫苗开发的一项努力。
NEC / NEC OncoImmunity AS：
应用用于个体化癌症疫苗开发的AI预测技术，分析SARS-CoV-2基因组序列。
使用预测算法分析所有蛋白质。
预测算法：
鉴定出包含重叠表位（可以作为疫苗靶标的对象）的多个“热点”。
此外，它可以被世界各地的许多人使用，
在病毒的蛋白质中，
我们优先选择突变少的那些，
为了确保安全，它不包括与人类蛋白质高度相似的蛋白质以及在重要器官中表达的蛋白质。
电脑手表
https://www.google.co.jp/amp/s/pc.watch.impress.co.jp/docs/news/1249/063/amp.index.html
NEC publishes design blueprints for SARS-CoV-2 vaccines using its AI technology:
Tokyo, April 23, 2020 –
NEC Corporation (NEC; TSE: 6701) today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines
that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19
and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE).
These AI prediction platforms
are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.
During the analysis,
which is published at bioRxiv,
the team analyzed thousands of sequences from the SARS-CoV-2 virus (responsible for causing COVID-19)
and identified epitopes (potential vaccine targets) for the 100 most frequent HLA alleles (diverse immunological makeup) in the global population.
The prediction algorithm
scanned for epitopes across the entire repertoire of proteins in SARS-CoV-2, not only the spike surface protein that gives this family of coronavirus its name.
The team then used this data to identify “hotspots” in the viral proteome that contained overlapping and co-located epitopes from multiple HLA-alleles.
The optimal constellation of “hotspots”
was then selected by their algorithms to generate the optimal immune response with the broadest coverage of the human population,
whilst prioritizing hotspots that occurred in conserved regions of the viral proteome.
These conserved regions are less likely to mutate in future strains. In addition, hotspots containing viral epitopes that had significant similarity with human proteins,
especially those expressed in critical organs, were removed from the vaccine design blueprints to avoid adverse effects.
The analysis
demonstrates the significant capabilities of the NEC Group to leverage their AI platforms to design blueprints for a vaccine
that is safe and efficacious in a global population and could address the current and future divergent strains of the SARS-CoV-2 virus.
NEC is now publishing this research
to support scientific advancements in the field and is ready to start partnering efforts to pursue the development of an effective vaccine targeting the global population.
Press Releases | NEC